Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 73.2% and 54.2% per annum respectively. EPS is expected to grow by 72.5% per annum. Return on equity is forecast to be -87.9% in 3 years.

Key information

73.2%

Earnings growth rate

72.5%

EPS growth rate

Biotechs earnings growth	27.5%
Revenue growth rate	54.2%
Future return on equity	-87.9%
Analyst coverage	Good
Last updated	04 Nov 2024

Recent future growth updates

Recent updates

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Nov 03

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Nov 02

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 24

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

Aug 09

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dec 20

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Aug 05

Madrigal: Buy And Hoard Before Q4 Data Readout

Aug 04

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Jul 08

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Earnings and Revenue Growth Forecasts

NasdaqGS:MDGL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	970	120	99	382	13
12/31/2025	576	-286	-226	-195	16
12/31/2024	169	-501	-530	-428	13
9/30/2024	77	-519	-438	-431	N/A
6/30/2024	15	-510	-456	-449	N/A
3/31/2024	N/A	-444	-391	-389	N/A
12/31/2023	N/A	-374	-326	-324	N/A
9/30/2023	N/A	-347	-303	-303	N/A
6/30/2023	N/A	-330	-277	-277	N/A
3/31/2023	N/A	-315	-259	-259	N/A
12/31/2022	N/A	-295	-225	-225	N/A
9/30/2022	N/A	-274	-215	-214	N/A
6/30/2022	N/A	-256	-201	-201	N/A
3/31/2022	N/A	-247	-191	-190	N/A
12/31/2021	N/A	-242	-184	-184	N/A
9/30/2021	N/A	-236	-191	-191	N/A
6/30/2021	N/A	-231	-193	-193	N/A
3/31/2021	N/A	-219	-171	-170	N/A
12/31/2020	N/A	-202	-158	-158	N/A
9/30/2020	N/A	-171	-115	-115	N/A
6/30/2020	N/A	-134	-79	-78	N/A
3/31/2020	N/A	-105	-66	-66	N/A
12/31/2019	N/A	-84	-42	-42	N/A
9/30/2019	N/A	-68	-36	-36	N/A
6/30/2019	N/A	-55	-30	-30	N/A
3/31/2019	N/A	-42	-23	-23	N/A
12/31/2018	N/A	-33	-26	-26	N/A
9/30/2018	N/A	-30	-25	-25	N/A
6/30/2018	N/A	-30	N/A	-25	N/A
3/31/2018	N/A	-32	N/A	-27	N/A
12/31/2017	N/A	-31	N/A	-22	N/A
9/30/2017	N/A	-30	N/A	-22	N/A
6/30/2017	N/A	-36	N/A	-26	N/A
3/31/2017	N/A	-31	N/A	-21	N/A
12/31/2016	N/A	-26	N/A	-18	N/A
9/30/2016	N/A	-21	N/A	-13	N/A
6/30/2016	N/A	-8	N/A	-5	N/A
3/31/2016	N/A	-7	N/A	-3	N/A
12/31/2015	N/A	-7	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: MDGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDGL is expected to become profitable in the next 3 years.

Revenue vs Market: MDGL's revenue (54.2% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: MDGL's revenue (54.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MDGL is forecast to be unprofitable in 3 years.

Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 59%

Consensus revenue estimates increase by 34%, EPS downgraded

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Recent updates

Consensus revenue estimates increase by 59%

Independent Director notifies of intention to sell stock

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 34%, EPS downgraded

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors